Antimicrobials
Favipiravir

Favipiravir

Spectrum of Activity

Dosing

General Information

Favipiravir is currently under investigation for use in the treatment of Coronavirus disease (COVID19)

  • Severe  hepatic impairment 
  • Pregnancy 
  • Breastfeeding

Women of child-bearing age confirmed negative pregnancy test before use.

Men: use effective contraception during and for 7days post-treatment (drug is distributed in sperm )

  • Diarrhea
  • Increased blood uric acid level 
  • Increased AST/ALT
  • Decreased neutrophil count

Pyrazinamide: Favipiravir may enhance the adverse /toxic effects of Pyrazinamide, the risk for increased uric acid concentrations, recommended: Monitor therapy 

Repaglinide: Favipiravir may increase the serum concentration of repaglinide, recommended: Monitor therapy.

Oral absorption: No data 

Average serum half-life: 5.6hr

Elimination: Metabolized by aldehyde oxidase and xanthine oxidase to hydroxylated metabolite eliminated in the urine 

CSF /Blood penetration: No data 

Biliary penetration: No data 

Pregnancy: Avoid use. Teratogenic

Breastfeeding: Contraindicated